AC Immune SA has reported encouraging interim results from its phase 2 VacSYn clinical trial of ACI-7104.056, an anti-alpha-synuclein (a-syn) active immunotherapy for early Parkinson’s disease (PD).

Researchers are using functionalized nanodiamonds to precisely monitor neuronal activity at the cellular level, enhancing ...

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

A research team reported recently that heart muscle cells grown from induced pluripotent stem cells can integrate into the hearts of monkeys with a state of pressure overload.

When I was diagnosed with Parkinson’s in August 2019, a doctor told me that Sinemet (Levodopa/Carbidopa), the starter drug of ...

Researchers released new clinical guidelines for treating restless legs syndrome (RLS), emphasizing patient-centered care and ...

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

2-Year U.S. Treasury Note Continuous Contract $102.668-0.031-0.03% 5-Year U.S. Treasury Note Continuous Contract $106.492-0.078-0.07% 10-Year U.S. Treasury Note Continuous Contract $109.313-0.109 ...